Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria~* Women aged 18 years and older~* Histologic or cytologic diagnosis of endometrial carcinoma~* Evidence that the cancer is advanced, recurrent, or metastatic and not curable by local measures, such as surgery or radiation.~* Karnofsky performance status \>=70~* Measurable or nonmeasurable disease that has progressed since last treatment.~  * If only disease is confined to a solitary lesion, its neoplastic nature must be confirmed by histology or cytology.~ * Disease in a previously irradiated field is acceptable as the only site of measurable disease only if there has been clear progression since completion of radiotherapy.~* All therapy directed at endometrial cancer must be discontinued 21 days prior to start of treatment, except for hormonal therapy which must be discontinued at least 1 week prior to start of study treatment. Concurrent administration of hormone replacement therapy is allowed.~* Prior therapy: Participants must have failed 1 prior platinum-based chemotherapeutic regimen for endometrial cancer. May have received 2 prior chemotherapy regimens if 1 regimen was given for stage I or II disease. May have received any number of prior non-cytotoxic regimens such as monoclonal antibodies, cytokines, signal transduction inhibitors, or hormonal therapy. Previous radiation therapy is allowed.~Key Exclusion Criteria~* Carcinosarcoma (malignant mixed mullerian tumor)~* Endometrial leiomyosarcoma and endometrial stromal sarcomas~* Participants who received no prior chemotherapy for endometrial cancer or ≥2 prior chemotherapy regimens (exceptions defined in protocol)~* Known brain metastases~* Receipt of prior ixabepilone therapy~* Concurrent active infection requiring antibiotics or other therapy~* Concurrent unstable disease or other debilitating illness, such as congestive heart failure, unstable angina, myocardial infarction, or other cardiac disease that could jeopardize participation, within the last 6 months~* For participants whose prior therapy did not include an anthracycline and therefore may be randomized to doxorubicin, left ventricular ejection fraction \<50% as measured by multigated radionuclide angiography or echocardiography~* History of malignancy, except nonmelanoma skin cancer, carcinoma in situ of the cervix, or carcinoma in situ of the breast, within the last 5 years that has not been treated with chemotherapy~* Known human immunodeficiency viral infection~* Psychiatric disorders or other conditions rendering the participant incapable of complying with protocol requirements~* Absolute neutrophil count \<1500/mm\^3~* Platelets \<100,000/mm\^3~* Hemoglobin \<9 g/dL~* Total bilirubin \>1.5\*upper limit of normal (ULN), except for those with Gilbert's disease~* Aspartate aminotransferase or alanine aminotransferase \>2.5\*ULN~* Serum creatinine \>1.5\*ULN~* Grade ≥2 neuropathy (sensory or motor)~* No concurrent therapy (chemotherapy, hormonal, or investigational) directed at endometrial cancer during the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ixabepilone, 40 mg/m^2, intravenously (IV) (Type: EXPERIMENTAL): Participants received ixabepilone, 40 mg/m\^2, given IV over 3 hours every 21 days until unacceptable toxicity or disease progression
- Control chemotherapy (Paclitaxel or Doxorubicin) (Type: ACTIVE_COMPARATOR): Participants received either paclitaxel, 175 mg/m\^2 given IV over 3 hours, or per institutional guidelines but not exceeding 3 hours, every 21 days until disease progression or unacceptable toxicity or doxorubicin, 60 mg/m\^2 given IV per institutional guidelines every 21 days, depending on the prior therapy received, until disease progression, unacceptable toxicity, or cumulative dose of 500 mg/m\^2.

Based on this trial design, predict the completion outcome and termination type (if applicable).